Surrogate markers in oncology practice and anticancer drug development: lessons learned from antiretroviral therapy?

Cancer Invest. 2004;22(1):164-8. doi: 10.1081/cnv-120027592.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Retroviral Agents / pharmacology*
  • Antineoplastic Agents / pharmacology*
  • Biomarkers / analysis*
  • Drug Design
  • Forecasting
  • HIV Infections / drug therapy
  • Humans
  • Medical Oncology / trends*
  • Neoplasms / drug therapy
  • Prognosis
  • Treatment Outcome

Substances

  • Anti-Retroviral Agents
  • Antineoplastic Agents
  • Biomarkers